Search PubMed⌕ Search

Biomedical subjects

S Ferrone

Publications and source records attributed to S Ferrone.

At least 559 records · Page 31Linked to original sources
PubMedDate not supplied

Human melanoma-associated antigens identified with monoclonal antibodies.

Using monoclonal antibodies three types of membrane-bound tumour-associated antigens have been identified on human melanoma cells. The tissue distribution, the immunological profile and the structural properties of these melanoma associated antigens (MAA) are described. The applications of the monoclonal antibodies to one of the MAA in the area of immunodiagnosis and immunotherapy are discussed.

Animals↗
PubMedDate not supplied

Receptor for complement components and xenogeneic erythrocytes on human T- and B-lymphoid cells.

Biological and molecular properties of receptors specific for human T- and B-lymphoid cells are discussed. Sensitive simple and reproducible methods to enumerate B- and T-lymphocytes are described: their possible application in clinical immunology is indicated. A new method to obtain enriched populations of human T- and B-lymphocytes from peripheral blood is described. This method appears to be suitable to investigate the properties of antigens specific for B- and T-lymphoid cells.

Antibody Formation↗
PubMedDate not supplied

Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma.

Following a description of the characteristics of the human high molecular weight-melanoma associated antigen (HMW-MAA), the rationale to use anti-idiotypic (anti-id) monoclonal antibodies (mAb) as immunogens to implement active specific immunotherapy in patients with malignant diseases is discussed. Among the anti-id mAb developed in this laboratory the mAb MK2-23, which had been elicited with the syngeneic anti-HMW-MAA mAb 763.74, has been shown with serological and immunochemical assays to bear the mirror image of the determinant recognized by mAb 763.74 on HMW-MAA. The anti-id mAb elicited humoral anti-HMW-MAA immunity in about 60% of patients with malignant melanoma. The immunogenicity of mAb MK2-23 is markedly enhanced by conjugation to a carrier and administration with an adjuvant, but is not affected by the administration of low doses of cyclophosphamide. Development of anti-HMW-MAA immunity in patients with malignant melanoma is associated with survival prolongation. These results in conjunction with the lack of major side effects in spite of repeated administrations of mAb MK2-23 suggest that active specific immunotherapy with mAb MK2-23 represents a useful therapeutic approach to malignant melanoma.

Animals↗
PubMedDate not supplied

Specific killing of human melanoma cells with an efficient 10B-compound on monoclonal antibodies.

We previously established methods which have enabled us to target a sufficient number of 10B atoms on human melanoma cells to destroy them by thermal neutron irradiation. Monoclonal antibodies were here used as vector of 10B atoms on the target cell. Thermal neutrons require at least 10(9) 10B atoms to destroy the cell. In order to accumulate an adequate number of 10B atoms on target cells, our first approach was to make an effective compound that contains 12 atoms of 10B in a molecule. The second step was to conjugate the compound with an avidin molecule (10B12-avidin). One molecule of the 10B12-avidin carries about 30 atoms of 10B. This 10B12-avidin can be specifically targeted on human melanoma cells by biotinated monoclonal antibodies specific for the cells. Furthermore, the number of 10B atoms on target cells can be augmented by a hapten-antihapten monoclonal antibody system. The cultured human melanoma cells treated with these methods were damaged by thermal neutron irradiation. This is the first study that indicates thermal neutrons do injure target cells boronated by monoclonal antibodies.

Antibodies, Monoclonal↗
PubMedDate not supplied

Expression and susceptibility to modulation by interferons of HLA class I and II antigens on melanoma cells. Immunohistochemical analysis and clinical relevance.

Immunohistochemical analysis for non-polymorphic determinants of HLA class I or class II antigens has been greatly facilitated by the use of monoclonal antibodies. Studies on the distribution of these antigens in tumour lesions emphasize their role in the tumour-host interaction and in tumour histopathology, especially as additional markers in the assessment of prognosis of melanoma patients. Changes in the expression of HLA antigens on tumour cells in vitro as induced by gamma-interferon may also occur in vivo as a result of local production by the T lymphocytic infiltrate in tumours.

Cells, Cultured↗
PubMedDate not supplied

Radioimmunodetection of melanoma: preliminary results of a prospective study.

A prospective study to evaluate the clinical usefulness of radioimmunodetection of melanoma in clinical practice is ongoing at the National Cancer Institute of Milan, Italy. Technical conditions for the application of the method were previously reported. In this trial, 99mTc-labelled F(ab')2 fragments of the 225.28S monoclonal antibody were used against a high molecular weight melanoma associated antigen (HMW-MAA). Retrospective studies on radioimmunodetection of melanoma have already been made by our group and by other Centers in about 300 patients. This study concerns the evaluation of the regional extension of primary melanoma. 23 patients with 32 suspected lymphatic involvements of melanoma on the trunk and arms underwent immunoscintigraphy. No false positive results were observed; 3 false negatives, one corresponding to a micrometastasis, were noticed. Specificity corresponds to 100% and sensitivity to 78.6%.

Adolescent↗
PubMedDate not supplied

New aspects in the treatment of immunomediated diseases.

The following constitutes a summary of lectures delivered during the session "New aspects in the treatment of immunomediated diseases" which was held during the 25th Annual Scientific Meeting of the European Society for Clinical Investigation in Pisa, Italy on 6th April 1991. The aim of this session was to present and discuss some of the novel therapeutic modalities currently being employed either in experimental models or in phase I clinical studies.

Adjuvants, Immunologic↗
PubMedDate not supplied

Human Ia-like antigens (Analysis of the tissue distribution and immunochemical profile with monoclonal antibodies).

Analysis of the tissue distribution of human Ia-like antigens has shown that they have a wider distribution than originally reported. Furthermore, the expression of Ia-like antigens may change when cells undergo malignant transformation: for instance, melanoma cells acquire Ia-like antigens, while breast carcinoma cells lose them. Serological and immunochemical analysis of Ia-like antigens with monoclonal antibodies has shown a cellular and molecular heterogeneity of these molecules which had not been previously recognized with conventional allo- and xenoantisera. The functional significance of this heterogeneity is not known. Monoclonal antibodies to human Ia-like antigens cross-react with lymphocytes from other animal species indicating that portions of the molecules have been conserved during evolution. The biological implications of these findings are discussed.

Animals↗